12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EC145: Additional Phase II data

Endocyte reported data from a supplemental analysis conducted by a blinded independent review committee of the open-label, international Phase II PRECEDENT trial in 149 patients with platinum-resistant ovarian cancer showing that thrice-weekly 2.5 mg IV EC145 every 2 weeks plus 50 mg/m 2 IV Doxil liposomal doxorubicin every 28 days non-significantly improved median PFS, the primary endpoint, vs. Doxil alone (4.2 vs. 2 months, p=0.2235). The combination also non-significantly improved the endpoint in patients with >=1 folate receptor-positive tumor (4 vs. 1.5 months, p=0.1449), but led to a significant improvement in patients with 100% folate receptor-positive tumors (4 vs. 1.5 months, p=0.0498). Previously, the company reported that an investigator's open-label assessment had shown that EC145 plus Doxil significantly improved PFS vs. Doxil alone (5 vs. 2.7 months, p=0.031) (see BioCentury, Jan. 31 & June 20)....

Read the full 663 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >